Tag: InVivo Therapeutics
An investigational scaffold device from InVivo Therapeutics increases the likelihood that a patient with acute thoracic complete spinal cord injury will have a neurologic status ‘conversion’ from complete paraplegia to incomplete injury, according to findings presented at the American Association of Neurological Surgeons 2018 Annual Meeting in New Orleans and detailed in Medscape.
Here are four things to know.
Patients suffering from complete spinal cord injuries have little to no treatment options that provide meaningful improvement in patient outcomes.
Cambridge, Mass.-based InVivo Therapeutics is trying to change that. Co-founded in 2005 by MIT professor Robert Langer, and surgeon-scientists Joseph Vacanti, M.D., the company has developed a small, bioresorbable and biocompatible device called the Neuro-Spinal Scaffold, to help patients with complete thoracic spinal cord injuries regain some function.
Jesi Stracham used to captivate biotech investors and inadvertently move markets with social media posts documenting her dogged quest to get out of her wheelchair and back onto her feet.
These days, the energetic 24-year-old North Carolina resident goes online to tell a different story. Many of her Facebook and Instagram posts show her competing in off-road vehicle races, an adaptive water skiing competition, and a pageant for women with disabilities.
“I really just want to show people that there is life to be had in the wheelchair,” Stracham said. “There is life to be had with wheels as legs.”
As we cross the threshold into 2016, we are one step closer to our goal of finding a cure for paralysis.
Moving full speed ahead towards that goal, Conquer Paralysis Now compiled a brief retrospective. 2015 has been an incredible year for spinal cord injury research, with breakthroughs in a variety of potential treatments, on top of important strides made by individuals with SCI. Take a look at some key milestones from this past year and stay tuned for what’s to come in 2016. Happy New Year!
In the age of social media, patients who test experimental treatments wield surprising clout.
The tweets and the selfies, the uploaded video clips, felt like a natural way for Jesi Stracham to record her halting progress as she fought to recover from a motorcycle accident that had left her paralyzed from the chest down.
She had no idea, as she tapped away at her iPhone from her hospital bed, what her bubbly posts would unleash.
- Four biotech companies are pursuing the treatment of spinal cord injury with the use of stem cell transplantation.
- Each company demonstrated efficacy in pre-clinical studies.
- The race is in the early stages but InVivo Therapeutics is clearly leading the pack based on its strategic approach to accelerated HDE approval and initial trial results.
The first two patients to receive InVivo’s Neuro-Spinal Scaffold for spinal cord injury are showing improvement three-to-six months after surgery.
The first spinal cord injury patient was treated in October 2014 at Barrow Neurological Institute in Phoenix and the second was treated in January 2015 at Carolinas Medical Center in Charlotte.
InVivo Therapeutics enrolled the second patient in their Neuro-Spinal Scaffold to treat traumatic spinal cord injury.
The patient is enrolled at Carolinas Medical Center, part of the Carolinas HealthCare System in the study to evaluate the safety and feasibility of the Neuro-Spinal Scaffold.
Scaffold Designed to Facilitate Neural Growth in Spinal Cord Injury
CAMBRIDGE, Mass.–(BUSINESS WIRE)–April 28, 2014– InVivo Therapeutics Holdings Corp. (NVIV) announced today that it has begun shipment of its innovative investigational device, a degradable polymer Neuro-Spinal Scaffold for spinal cord injury (SCI) patients, for initiation of the company’s first clinical trial. InVivo has pioneered a new treatment platform utilizing a biocompatible polymer-based device that is intended to promote structural support for spinal cord regeneration while improving functional recovery and prognosis after a traumatic SCI. In preclinical studies, the Neuro-Spinal Scaffold promoted cell adhesion, neurite sprouting, the growth of remodeled spinal cord tissue containing myelinated axons, and improved motor function.
Could a cure for paralysis be in the near future? Invivo Therapeutics shows technology minimizing tissue damage after a spinal cord injury